學(xué)習(xí)經(jīng)歷：
2005-2009????華中科技大學(xué)同濟藥學(xué)院?? 中藥學(xué) 學(xué)士
2009-2014????中國科學(xué)院廣州生物醫(yī)藥與健康研究院?? 藥物化學(xué) 博士
?
工作經(jīng)歷
2014-2015????美國梅奧醫(yī)院 (Mayo Clinic)??? 博士后
2015-2019????明尼蘇達大學(xué)藥物化學(xué)系/Masonic癌癥中心 博士后
2019-2023????明尼蘇達大學(xué)Masonic癌癥中心?? Researcher 6
2021-2023????明尼蘇達大學(xué)藥物化學(xué)系?? 研究助理教授
2023-2025????德克薩斯大學(xué)El Paso分校藥物科學(xué)系??? 助理教授
2026-現(xiàn)在????中國科學(xué)院廣州生物醫(yī)藥與健康研究院?? 研究員
1.?細胞信號轉(zhuǎn)導(dǎo)的時空解碼與化學(xué)干預(yù)。
我們將運用高分辨率質(zhì)譜技術(shù)，系統(tǒng)繪制細胞命運決定中關(guān)鍵信號轉(zhuǎn)導(dǎo)分子的動態(tài)圖譜，并以此為基礎(chǔ)開發(fā)靶向性化學(xué)干預(yù)工具，旨在實現(xiàn)對病理信號通路的精準糾偏和功能重塑。
2.?新型靶向藥物設(shè)計、合成及生物學(xué)評價。
我們將聚焦于惡性腫瘤、自身免疫性疾病等重大疾病領(lǐng)域的未滿足臨床需求，以“化學(xué)適配”策略（Acc Chem Res, 2025, 58, 3195-3209）為指導(dǎo)，運用抗體偶聯(lián)藥物、小分子降解劑等前沿藥物開發(fā)技術(shù)，針對關(guān)鍵靶點進行原創(chuàng)藥物設(shè)計。依托完整的臨床前藥理學(xué)評價體系，高效推進優(yōu)秀候選化合物向臨床轉(zhuǎn)化。
2023?? Rising STARs Award, The University of Texas System
2019?? Travel Award, Division of Chemical Toxicology, American Chemical Society
2015???廣州市科學(xué)技術(shù)獎一等獎
截止目前，共在本研究領(lǐng)域發(fā)表期刊論文30余篇，授權(quán)發(fā)明專利4項。
近五年發(fā)表論文（# co-first author; * corresponding author）
[1]?Ding K*, Li Y, Zhou Y, Huang W. Chemical Adaptation in Drug Discovery: The Medicinal Chemistry Journey of Olverembatinib and Limertinib in Overcoming Kinase Drug Resistance.Acc. Chem. Res. 2025, 58(20), 3195-3209.
[2]?Zhang H, Li Y*. Temozolomide-Derived Therapeutic Strategies to Overcome Resistance in Glioblastoma. J. Med. Chem. 2025, 68(18), 18810-18828.
[3]?Guo W#, Gao Y#, Du D, Sanchez JE, Li Y, Qiu W*, Li L*. Elucidating the interactions between Kinesin-5/BimC and the microtubule: insights from TIRF microscopy and molecular dynamics simulations. Brief. Bioinform, 2025, 26(2), bbaf144.
[4]?Zhang H#, Tu Y#, Tao Z#, Gao L, Huang S, Gao M, Mao J, Zhou Y, Li Y, Li J*, Zhou Y*, Xu T*. Design, synthesis and biological evaluation of 2,4-diaminopyrimidine derivatives as potent cyclin-dependent kinase 7 inhibitors. ACS Med Chem Lett 2024, 15(8), 1213-1220.
[5]?Li Y*, Tang MK*, Carmella SG, Peters CP, Cohen JD, Hegeman AD, Hecht SS*. Hydroponic growth of [13C]-labeled tobacco for DNA damage studies in cigarette smokers. J Agric Food Chem 2024, 72 (30), 16594-16602. (Cover Paper)
[6]?Li Y*. DNA adducts in cancer chemotherapy. J. Med. Chem. 2024, 67 (7), 5113-5143.
[7]?Fabitha K, Kallingal A, Maciejewska N, Arya CG, Chandrakanth M, Thomas NM, Li Y, Gondru R, Munikumar M, Banothu J*. Revealing novel fused pyran derivatives: Their discovery as potent anticancer agents and mechanistic insights. New J Chem 2024, 48, 8038-8054. (Cover Paper)
[8]?Zhou C#, Fan Z#, Gu Y#, Ge Z#, Tao Z, Cui R, Li Y, Zhou G, Huo R, Gao M, Wang D, He W, Zheng M*, Zhang S*, Xu T*. Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D. J. Med. Chem. 2024, 67 (2), 1147-1167.
[9]?Li Y*, Dator R, Maertens L, Balbo S, Hecht SS. Mass spectrometry-based metabolic profiling of urinary metabolites of N′-nitrosonornicotine (NNN) in the rat. Chem. Res. Toxicol. 2023, 36 (5), 769-781. (Cover Paper)
[10]?Guidolin V#, Li Y#, Jacobs F, MacMillan ML, Villalta PW, Hecht SS, Balbo S*. Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy. Mol. Ther. Oncolytics. 2023, 28, 197-210.
[11]?Zhou Z#, Zhou G#, Zhou C#, Fan Z, Cui R, Li Y, Li R, Gu Y, Li H, Ge Z, Cai X, Jiang B, Wang D, Zhang S*, Xu T*, Zheng M*. Discovery of a potent and selective SOS1 PROTAC ZZ151: Exploration of degradation activity cliffs and antitumor efficacy in KRAS-mutated cancers. J. Med. Chem. 2023, 66 (6), 4197-4214.
[12]?Liu M#, Zhou G#, Su W#, Gu Y, Gao M, Wang K, Huo R, Li Y, Zhou Z, Chen K, Zheng M, Zhang S*, Xu T*. Design, synthesis and bioevaluation of pyrido[2,3-d]pyrimidin-7-ones as potent SOS1 inhibitors. ACS Med. Chem. Lett. 2023, 14 (2), 183-190.
[13]?Zhang Y#, Guo R#, Chen Y, Li T, Du W, Xiang R, Guang J, Li Y, Huang Y, Yu Z, Cai Y, Zhang P*, Ling G*. Ionizable drug delivery systems for efficient and selective gene therapies. Mil. Med. Res. 2023, 10 (1), 9.
[14]?Li Y*, Hecht SS. Mass spectrometric quantitation of N′-Nitrosonornicotine-1N-oxide in the urine of cigarette smokers and smokeless tobacco users. Chem. Res. Toxicol. 2022, 35, 1579-1588. (Cover Paper)
[15]?Li Y*, Hecht SS. Metabolic activation and DNA interactions of carcinogenic N-nitrosamines to which humans are commonly exposed. Int. J. Mol. Sci. 2022, 23 (9), 4559.
[16]?Li Y*, Hecht SS. Metabolism and DNA adduct formation of tobacco-specific N-nitrosamines. Int. J. Mol. Sci. 2022, 23 (9), 5109.
[17]?Li Y*, Hecht SS*. Carcinogenic components of tobacco and tobacco smoke: A 2022 update. Food Chem. Toxicol. 2022, 165, 113179.
[18]?Arya CG, Gondru R, Li Y*, Banothu J*. Coumarin–benzimidazole hybrids: a review of developments in medicinal chemistry. Eur. J. Med. Chem. 2022, 227, 113921.
[19]?Fabitha K, Chandrakanth M, Pramod RN, Arya CG, Li Y, Banothu J*. Recent developments in the synthesis of indole-pyrazole hybrids. ChemistrySelect 2022, 7, e202201064.
[20]?Zhou C#, Fan Z#, Zhou Z#, Li Y, Cui R, Liu C, Zhou G, Diao X, Jiang H, Zheng M*, Zhang S*, Xu T*. Discovery of the first-in-class agonist-based SOS1 PROTACs effective in human cancer cells harboring various KRAS mutations. J. Med. Chem. 2022, 65, 3923-3942.
[21]?Zhang H#, Xie R#, AI-furas H, Li Y, Wu Q, Li J*, Xu F*, Xu T*. Design, synthesis and biological evaluation of novel EGFR PROTACs targeting Del19/T790M/C797S mutation. ACS Med. Chem. Lett. 2022, 13, 278-283.
[22]?Li Y, Carlson ES, Zarth AT, Upadhyaya P, Hecht SS*. Investigation of 2′-deoxyguanosine-derived adducts specifically formed in rat liver and lung DNA by N′-nitrosonornicotine (NNN) metabolism. Chem. Res. Toxicol. 2021, 34 (4), 1004-1015.
[23]?Li Y, Hecht SS*. Identification of an N′-nitrosonornicotine-specific deoxyguanosine adduct in rat liver and lung DNA. Chem. Res. Toxicol. 2021, 34 (4), 992-1003.
已授權(quán)專利
[1]?David S, Li Y, Brush M, Trautman K, Gustafson C, Maurer D, Pathakumari B. Therapeutic compounds and methods of use thereof. US12060350B2, granted on 08/2024.
[2]?Ding K, Lu X, Zhang T, Tang J, Lu M, Li Y, Zhang Z, Liang Z, Qian Z. Preparation method and use of N-4-trifluoromethylphenylsalicylamide derivatives. CN104873522(B), granted on 06/2019.
[3]?Ding K, Li Y, Shen M, Long H, Zhang Z, Leng F, Lu X. Heterocylic benzamide compounds, pharmaceutical compositions as well as application thereof. CN103539784(B), granted on 08/2016.
[4]?Ding K, Feng Y, Lu X, Li W, Li Y, Shen M. Synthesis method of ponatinib. CN103570724(B), granted on 12/2015.
